Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Resverlogix Thinks RVX-208 Can Succeed At Reducing Arterial Plaque Where Pfizer's Torcetrapib Failed

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Resverlogix believes its small-molecule drug RVX-208 delivers on a key goal in cardiovascular drug development - the ability to clear life-threatening plaque out of arteries - setting the firm up to succeed with its first-in-class agent where others have failed and to write its own ticket in the $35 billion cholesterol market

You may also be interested in...



Resverlogix Plays Up Importance Of New Study After Missing Phase II Endpoint

Resverlogix Corp. says it is keeping its faith in RVX-208 – a cholesterol drug designed to improve HDL function – despite missing a primary efficacy endpoint in the Phase II ASSERT trial, facing questions over a newly seen liver signal, and suffering a major blow to its stock price.

Resverlogix Plays Up Importance Of New Study After Missing Phase II Endpoint

Resverlogix Corp. says it is keeping its faith in RVX-208 – a cholesterol drug designed to improve HDL function – despite missing a primary efficacy endpoint in the Phase II ASSERT trial, facing questions over a newly seen liver signal, and suffering a major blow to its stock price.

Resverlogix Plays Up Importance Of New Study After Missing Phase II Endpoint

Continuing in its quest for the holy grail of a novel HDL cholesterol drug, Resverlogix maintains that an upcoming Phase IIb trial will test a more appropriate, higher-risk population and study patients longer.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel